Loading...
Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
BACKGROUND: Researches on programmed cell death (PD-1) as neoadjuvant immunotherapy for resectable non-small cell lung cancer is underway, which brings hope for individuals with the disease. However, a study dedicated to lung squamous cell carcinoma (LUSC) specifically has yet to be conducted. Now,...
Na minha lista:
| Udgivet i: | J Thorac Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8024839/ https://ncbi.nlm.nih.gov/pubmed/33841966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-21-103 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|